Southwest Cancer Treatment & Research Center — Lubbock, Texas

Southwest Cancer Treatment & Research Center is a clinical research site located in Lubbock, Texas, United States 79415.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Southwest Cancer Treatment & Research Center has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute.

Sponsors: Celgene, Center for International Blood and Marrow Transplant Research.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Lubbock

Browse all research sites in Texas · View every site in Lubbock

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Southwest Cancer Treatment & Research Center?

Southwest Cancer Treatment & Research Center has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Southwest Cancer Treatment & Research Center conducted?

Southwest Cancer Treatment & Research Center has 2 clinical trials on record, with 1 currently active. Their work covers Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute.

Is Southwest Cancer Treatment & Research Center accredited by Crixeo Clinical Trials?

Southwest Cancer Treatment & Research Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Southwest Cancer Treatment & Research Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.